Shots:

• Immatics to get $75M up front and is also eligible to receive ~$505M as option exercise fee for each licensed product including development- regulatory & commercial milestone plus royalties on sales. Immatics may develop TCR-T targets for solid tumors based on its XPRESIDENT technology- will take care of development & validation of the programs through lead candidate stage
• Celgene to get exclusive option rights to license Immatics’ three TCR-T targets post lead candidate stage and will take care of WW development- manufacturing and commercialization of therapies. Additionally- Immatics may also have early stage co-development or co-funding rights of the therapies    
• Immatics’ XPRESIDENT technology is a used to develop immunotherapies targeting cancer with the identification of novel- highly specific and accurate targets usually present on human leucocyte antigen (HLA) receptors on the surface of tumor cells

Click here to read full press release/ article | Ref: Immatics | Image: Twitter